Renin angiotensin system blockade and activated vitamin D as a means of preventing deep vein thrombosis in renal transplant recipients

Clinical Nephrology

Volumn 75, Issue 5, 2011, Pages 440-450

  Moscarelli, L ^a   Zanazzi, M ^a   Bertoni, E ^a   Caroti, L ^a   Rosso, G ^a   Farsetti, S ^a   Annunziata, F ^a   Paudice, N ^a   Salvadori, M ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Calcitriol; Renal transplant; Venous thromboembolism

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCITRIOL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HEPARIN; IRBESARTAN; LISINOPRIL; LOSARTAN; RAMIPRIL; TELMISARTAN; VALSARTAN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; VENOUS THROMBOEMBOLISM; ADOLESCENT; MIDDLE AGED; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCITRIOL; FEMALE; HUMANS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VENOUS THROMBOSIS;

EID: 79958743741     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP75440     Document Type: Article

References (38)

1. Kazory A, Ducloux D. Acquired hypercoagulable state in renal transplant recipients. Thromb Haemost. 2004; 91: 646-656.
2. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. The coagulo-lytic system and endothelial function cyclosporine-treated kidney allograft recipients. Transplantation. 1996; 62: 828-830.
3. Poli D, Zanazzi M, Antonucci E, et al. High rate of recurrence in renal transplant recipients after a first episode of venous thromboembolism. Transplantation. 2005; 80: 789-793.
4. Wu-Wong JR, Nakane M, MA J. Effects of vitamin D analogs on the expression of plasminogen activator inhibitor-1 in human vascular cells. Thrombosis Reseach. 2006; 118: 709-714.
5. Leizorovicz A, Cohen AT, Turpie AG et al. For PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004; 110: 874-879.
6. Samama MM, Cohen AT, Darmon JY et al .Acomparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in medical patients with Enoxaparin Study Group. N Engl J Med. 1999; 341: 793-800.
7. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic and urologic surgery. N Engl J Med. 1988; 318: 1162-1173.
8. Moser KM, Fedullo PF, LitteJohn JK et al. Frequent asymtomatic pulmonary embolism in patients with deep venous thrombosis. JAMA. 1994; 271:223-225.
9. Vaitkus PT, Leizorovicz A, Cohen AT et al. PREVENT Medical Thromboprophylaxis Study Group. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost. 2005; 93: 76-79.
10. Barbosa EM, Nonogaki S, Katayama ML et al.Vitamin D3 modulation of plasminogen activator inhibitor type1 in human breast carcinomas under organ culture. Virchows Archiv. 2004; 444: 175-182.
11. Koyama T, Shibakura M, OhsawaMet al. Anticoagulant effects of 1 alpha, 25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes. Blood. 1998; 92: 160-167.
12. Ohsawa M, Koyama T, Yamamoto K et al. 1alpha, 25-dihydroxivytamin D3 and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation. 2000; 102: 2867-2872.
13. Gyetko MR, Webb AC, Sitrin RG. Modulation of urokinase-type plasminogen activator and plaminogen activator inhibitor-2expression by U-937 mononuclear phagocytes. Effects of 1alpha,25-dihydroxyvitamin D3 and phorbol ester. Journal of Immunology. 1988; 141: 2693-2698.
14. Katoh T, Maeda Y, Yamato H et al. Effect of 24R,25-dihydroxivytamin D3 in experimental diabetic rats. Journal of Internal Medicine Research. 1998; 16: 300-304.
15. Aihara K, Azuma H, AkaikeMet al. Disruption of nuclear vitamin D receptor gene causes enhanced thrombogenicity in mice. Journal of Biological Chemistry. 2004; 279: 35798-35802.
16. Beer TM, Venner PM, Ryan CW et al. High dose calcitriol may reduce thrombosis in cancer patients. British Journal of Haematology. 2006; 135: 392-394.
17. Nadar SK, Blann AD, Kamath S et al. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol. 2004; 44: 415-422.
18. Sechi LA, Zingaro L, Catena C et al. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertension. Hypertension. 2000; 36: 978-985.
19. Spencer CGC, Martin SC, FelmdenDCet al. Relationship of homocysteine to markers of platelet and endothelial activation in ' high risk' hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial. Int J Cardiol. 2004; 94: 293-300.
20. Dielis AWJH, Smid M, Spronk HMN et al. Changes in fibrinolytic activity after angiotensin II receptor blockade in therapy-resistant hypertensive patients. J Thromb Haemost. 2007; 5: 1509-1515.
21. Sakata K, Pawlak R, Urano T et al. Effects of a long-term pharmacological interruption of the renin-angiotensin system on the fibrinolytic system in essential hypertension. Pathophysiol Haemost Thromb. 2002; 32: 67-75.
22. Remkova A, RemkoM. The role of renin-angiotensin system in prothrombotic state in essential hypertension. Physiol Res. 2010; 59: 13-23.
23. Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol. 2000; 11: S1.
24. Solez K, Axelsen RA, Benediktsson H et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int. 1993; 44: 411-421.
25. Hankey GJ, Eikelboom JW. Homocysteine and vascular disease. Lancet. 1999; 354: 407.
26. Bergqvist D, Bergentz SE, Bornmyr S et al. Deep vein thrombosis after renal transplantation: a prospective analysis of frequency and risk factors. Eur Surg Res. 1985; 17: 69.
27. Allen RD, Michie CA, Murie JA et al. Deep venous thrombosis after renal transplantation. Surg Gynecol Obset. 1987; 164: 137-142.
28. Ozsoylu S, Strauss HS, Diamond LK. Effects of corticosteroids on coagulation of the blood. Nature. 1962; 195: 1214-1218.
29. Patrassi GM, Sartori MT, Rigotti P et al. Coagulation and fibrinolysis during the first year of immunosuppressive treatment in renal transplantation: correspondence between hypercoagulable state and steroid therapy. Clin Appl Thrombosis Hemosta. 1995; 1: 277-281.
30. Boushey CJ, Beresfor SSA, GSO et al. Aquantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA. 1995; 274: 1049-1057.
31. Den Heijer M, Koster T, Blom HJ et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Eng J Med. 1996; 334: 759-762.
32. Ducloux D, Motte G, Challier B et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol. 2000; 11: 134-137.
33. Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron. 1997; 76: 56-61.
34. Snyder JJ, Kasiske BL, Gilbertson DT et al. Acomparison of transplant outcomes in peritoneal and hemodialysis patients. Kidney Int. 2002; 62: 1423-1430.
35. Kahan BD, Ponticelli C, Aroldi A et al. Musculoskeletal, ocular and hematological complications. In: Kahan BD, Ponticelli C (eds.). Principles and practice of renal transplantation. London: Martin Dunitz; 2000. p. 693-719.
36. Toyoda M, Galfayan k, Galera OA et al. CMV infection induces antiendothelial cell antibodies in cardiac and renal graft recipients. Transplant Immun. 1997; 5: 104-111.
37. Sumrani NB, Daskalakis P, Miles AM et al. Erythrocytosis after renal transplantation: a prospective analysis. ASAIO J. 1993; 39: 51-55.
38. Prandoni P, Falangia A, Piccioli P. Cancer and venous thromboembolism. Lancet Oncol. 2005; 6: 401-410.